Spruce Biosciences announced a proposed public offering of common stock and pre-funded warrants on March 9, 2026.2
An underwritten public offering commenced on April 20, 2026, with joint book-runners named, ongoing until May 20, 2026.2
The company filed a 424B5 prospectus on April 9, 2026, seeking capital through this offering.2
This follows a private placement financing raising approximately $50 million in gross proceeds from common stock and pre-funded warrants to advance TA-ERT for MPS IIIB toward BLA submission and potential commercial launch.2
Spruce's stock trades on the Nasdaq Capital Market under symbol SPRB, after a 1-for-75 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.2